PDF herunterladen
Z Gastroenterol 2004; 42(8): 692-697
DOI: 10.1055/s-2004-813439
Leitlinie

© Karl Demeter Verlag im Georg Thieme Verlag KG Stuttgart · New York

Vorgehen bei Problemsituationen bei der chronischen Hepatitis B

Treatment of Problematic Patients with Hepatitis BH. E. Blum1 , T. Berg2 , H. L. Tillmann3 , F. von Weizsäcker1
  • 1Albert-Ludwigs-Universität, Innere Abteilung II, Freiburg
  • 2Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charité - Universitätsmedizin Berlin, Campus-Virchow-Klinikum, Berlin
  • 3Universität Leipzig, Medizinische Klinik und Poliklinik II, Leipzig
Weitere Informationen

Publikationsverlauf





Publikationsdatum:
16. August 2004 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Die vorliegenden Konsensusempfehlungen stellen Richtlinien für das Management von Problemsituationen bei der Hepatitis-B-Virusinfektion dar. Generell wird empfohlen, in diesen Situationen ein spezialisiertes Zentrum zu kontaktieren. Die in den folgenden Abschnitten erwähnten Therapeutika sollten wie folgt dosiert werden: Lamivudin 100 mg p. o. täglich, Adefovir 10 mg p. o. täglich, Interferon-α 3 × 5 - 10 Mio IE pro Woche. Für weitere in klinischer Erprobung befindliche Therapeutika siehe Leitlinie „Standardtherapie der chronischen Hepatitis B”.

Literatur

  • 1 Tassopoulos N C, Volpes R, Pastore G. et al . Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group.  Hepatology. 1999;  29 889-896 (Ib)
    CrossrefPubMedGoogle Scholar
  • 2 Teuber G, Lohr H F, Kallinowski B. et al . Retrospektive Kohortenstudie zur Lamivudintherapie bei Patienten mit chronischer Hepatitis B.  Dtsch Med Wochenschr. 2001;  126 97-102 (III)
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 3 Hadziyannis S J, Papatheodoridis G V, Vassilopoulos D. Treatment of HBeAg-negative chronic hepatitis B.  Semin Liver Dis. 2003;  23 81-88 (Übersicht)
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 4 Hadziyannis S J, Tassopoulos N C, Heathcote E J. et al . Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.  N Engl J Med. 2003;  348 800-807 (Ib)
    CrossrefPubMedGoogle Scholar
  • 5 Lok A S, Heathcote E J, Hoofnagle J H. Management of hepatitis B: 2000 - summary of a workshop.  Gastroenterology. 2001;  120 1828-1853 (Übersicht)
    PubMedGoogle Scholar
  • 6 Perrillo R, Tamburro C, Regenstein F. et al . Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus.  Gastroenterology. 1995;  109 908-916 (IIb)
    PubMedGoogle Scholar
  • 7 Nair S, Perrillo R P. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia.  Hepatology. 2001;  34 1021-1026 (IIb)
    CrossrefPubMedGoogle Scholar
  • 8 Hoofnagle J H, Di Bisceglie A M, Waggoner J G. et al . Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B.  Gastroenterology. 1993;  104 1116-1121 (III)
    PubMedGoogle Scholar
  • 9 Fontana R J, Hann H W, Perrillo R P. et al . Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy.  Gastroenterology. 2002;  123 719-727 (IIa)
    CrossrefPubMedGoogle Scholar
  • 10 Yao F Y, Bass N M. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection.  J Hepatol. 2000;  33 301-307 (IIb)
    CrossrefPubMedGoogle Scholar
  • 11 Yao F Y, Terrault N A, Freise C. et al . Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort.  Hepatology. 2001;  34 411-416 (IIb)
    CrossrefPubMedGoogle Scholar
  • 12 Kapoor D, Guptan R C, Wakil S M. et al . Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis.  J Hepatol. 2000;  33 308-312 (IIb)
    CrossrefPubMedGoogle Scholar
  • 13 Villeneuve J P, Condreay L D, Willems B. et al . Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B.  J. Hepatology. 2000;  31 207-210 (IIb)
    CrossrefPubMedGoogle Scholar
  • 14 Perrillo R P, Wright T, Rakela J. et al . A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.  Hepatology. 2001;  33 424-432 (IIb)
    CrossrefPubMedGoogle Scholar
  • 15 Roche B, Samuel D. Liver transplantation for hepatitis B virus-related liver disease: indications, prevention of recurrence and results.  J Hepatol. 2003;  39 (Suppl. I) 181-189 (Übersicht)
    CrossrefPubMedGoogle Scholar
  • 16 Steinmuller T, Seehofer D, Rayes N. et al . Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease.  Hepatology. 2002;  35 1528-1535 (III)
    CrossrefPubMedGoogle Scholar
  • 17 Schiff E R, Lai C L, Neuhaus P. et al . Hepatology. 2002;  36 371A (IIb)
    PubMed
  • 18 Lok A S. Prevention of recurrent hepatitis B post-liver transplantation.  Liver Transpl. 2002;  8 67-73 (Übersicht)
    CrossrefPubMedGoogle Scholar
  • 19 Bienzle U, Gunther M, Neuhaus R. et al . Successful hepatitis B vaccination in patients who underwent transplantation for hepatitis B virus-related cirrhosis: preliminary results.  Liver Transpl. 2002;  8 562-564 (III)
    CrossrefPubMedGoogle Scholar
  • 20 Berenguer M, Wright T. Treatment of recurrence of hepatitis B in transplant patients.  J Hepatol. 2003;  39 (Suppl. I) 190-193 (Übersicht)
    CrossrefPubMedGoogle Scholar
  • 21 Bock C T, Tillmann H L, Torresi J. et al . Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation.  Gastroenterology. 2002;  122 264-273 (III)
    PubMedGoogle Scholar
  • 22 Kruger M, Tillmann H L, Trautwein C. et al . Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study.  Liver Transpl Surg. 1996;  2 253-262 (IIb)
    PubMedGoogle Scholar
  • 23 Tillmann H L, Trautwein C, Bock C T. et al . Lamivudine transiently reduces viral load and improves liver function in liver transplant recipients with fibrosing cholestatic hepatitis.  Am J Gastroenterol. 2002;  97 777-778 (IIb)
    CrossrefPubMedGoogle Scholar
  • 24 Kliem V, Ringe B, Holhorst K. et al . Kidney transplantation in hepatitis B surface antigen carriers.  Clin Investig. 1994;  72 1000-1006 (III)
    CrossrefPubMedGoogle Scholar
  • 25 Rao K V, Kasiske B L, Anderson W R. Variability in the morphological spectrum and clinical outcome of chronic liver disease in hepatitis B-positive and B-negative renal transplant recipients.  Transplantation. 1991;  51 391-396 (III)
    PubMedGoogle Scholar
  • 26 Aroldi A, Tarantino A, Montagnino G. et al . Renal transplant recipients and chronic liver disease: statistical evaluation of predisposing factors.  Nephron. 1992;  61 290-292 (III)
    PubMedGoogle Scholar
  • 27 Fairley C K, Mijch A, Gust I D. et al . The increased risk of fatal liver disease in renal transplant patients who are hepatitis Be antigen and/or HBV DNA positive.  Transplantation. 1991;  52 497-500 (III)
    PubMedGoogle Scholar
  • 28 Tillmann H L, Wedemeyer H, Manns M P. Treatment of hepatitis B in special patient groups: hemodialysis, heart and renal transplant, fulminant hepatitis, hepatitis B virus reactivation.  J. Hepatol. 2003;  39 (Suppl. I) 206-211 (Übersicht)
    CrossrefPubMedGoogle Scholar
  • 29 Al F araidy K, Yoshida E M, Davis J E. et al . Alteration of the dismal natural history of fibrosing cholestatic hepatitis secondary to hepatitis B virus with the use of lamivudine.  Transplantation. 1997;  64 926-928 (III)
    PubMedGoogle Scholar
  • 30 Chan T M, Wu P C, Li F K. et al . Treatment of fibrosing cholestatic hepatitis with lamivudine.  Gastroenterology. 1998;  115 177-181 (III)
    PubMedGoogle Scholar
  • 31 Jung S, Lee H C, Han J M. et al . Four cases of hepatitis B virus-related fibrosing cholestatic hepatitis treated with lamivudine.  J Gastroenterol Hepatol. 2002;  17 345-350 (III)
    CrossrefPubMedGoogle Scholar
  • 32 Natov S N, Pereira B J. Transmission of viral hepatitis by kidney transplantation: donor evaluation and transplant policies (Part 1: hepatitis B virus).  Transpl Infect Dis. 2002;  4 117-123 (Übersicht)
    CrossrefPubMedGoogle Scholar
  • 33 Prieto M, Gomez M D, Berenguer M. et al . De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population.  Liver Transpl. 2001;  7 51-58 (III)
    CrossrefPubMedGoogle Scholar
  • 34 Dodson S F, Issa S, Araya V. et al . Infectivity of hepatic allografts with antibodies to hepatitis B virus.  Transplantation. 1997;  64 1582-1584 (III)
    PubMedGoogle Scholar
  • 35 Dickson R C, Everhart J E, Lake J R. et al . Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database.  Gastroenterology. 1997;  113 1668-1674 (III)
    CrossrefPubMedGoogle Scholar
  • 36 Douglas D D, Rakela J, Wright T L. et al . The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient.  Liver Transpl Surg. 1997;  3 105-111 (III)
    CrossrefPubMedGoogle Scholar
  • 37 Lok A S, Liang R H, Chiu E K. et al . Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.  Gastroenterology. 1991;  100 182-188 (III)
    PubMedGoogle Scholar
  • 38 Nakamura Y, Motokura T, Fujita A. et al . Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991.  Cancer. 1996;  78 2210-2215 (III)
    CrossrefPubMedGoogle Scholar
  • 39 Kumagai K, Takagi T, Nakamura S. et al . Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan.  Ann Oncol. 1997;  8 (Suppl. 1) 107-109 (III)
    CrossrefPubMedGoogle Scholar
  • 40 Markovic S, Drozina G, Vovk M. et al . Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients.  Hepatogastroenterology. 1999;  46 2925-2930 (III)
    PubMedGoogle Scholar
  • 41 Yeo W, Chan P K, Zhong S. et al . Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors.  J Med Virol. 2000;  62 299-307 (III)
    CrossrefPubMedGoogle Scholar
  • 42 Lau G K, Liang R, Chiu E K. et al . Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study.  Bone Marrow Transplant. 1997;  19 795-799 (III)
    CrossrefPubMedGoogle Scholar
  • 43 Chen P M, Chiou T J, Fan F S. et al . Fulminant hepatitis is significantly increased in hepatitis B carriers after allogeneic bone marrow transplantation.  Transplantation. 1999;  67 1425-1433 (III)
    CrossrefPubMedGoogle Scholar
  • 44 Dhedin N, Douvin C, Kuentz M. et al . Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc.  Transplantation. 1998;  66 616-619 (III)
    CrossrefPubMedGoogle Scholar
  • 45 Romand F, Michallet M, Pichoud C. et al . Hepatitis B virus reactivation after allogeneic bone marrow transplantation in a patient previously cured of hepatitis B.  Gastroenterol Clin Biol. 1999;  23 770-774 (III)
    PubMedGoogle Scholar
  • 46 Iwai K, Tashima M, Itoh M. et al . Fulminant hepatitis B following bone marrow transplantation in an HBsAg-negative, HBsAb-positive recipient; reactivation of dormant virus during the immunosuppressive period.  Bone Marrow Transplant. 2000;  25 105-108 (III)
    CrossrefPubMedGoogle Scholar
  • 47 Cheng A L. Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma.  Blood. 1996;  87 1202 (IIb)
    PubMedGoogle Scholar
  • 48 Yeo W, Steinberg J L, Tam J S. et al . Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy.  J Med Virol. 1999;  59 263-269 (IIb)
    CrossrefPubMedGoogle Scholar
  • 49 ter B org F, Smorenburg S, de Man R A. et al . Recovery from life-threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy.  Dig Dis Sci. 1998;  43 2267-2270 (IIb)
    CrossrefPubMedGoogle Scholar
  • 50 Farrell G C. Immunosuppression and reactivation of hepatitis B in the lamivudine era: opportunities for prevention and exploitation.  J Gastroenterol Hepatol. 1999;  14 741-744 (Editorial)
    PubMedGoogle Scholar
  • 51 Ahmed A, Keeffe E B. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection.  Am J Gastroenterol. 1999;  94 249-251 (III)
    CrossrefPubMedGoogle Scholar
  • 52 Clark F L, Drummond M W, Chambers S. et al . Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma.  Ann Oncol. 1998;  9 385-387 (III)
    CrossrefPubMedGoogle Scholar
  • 53 Lee W C, Wu M J, Cheng C H. et al . Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients.  Am J Kidney Dis. 2001;  38 1074-1081 (IIa)
    PubMedGoogle Scholar
  • 54 Silvestri F, Ermacora A, Sperotto A. et al . Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation.  Br J Haematol. 2000;  108 394-396 (III)
    CrossrefPubMedGoogle Scholar
  • 55 Rossi G, Pelizzari A, Motta M. et al . Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.  Br J Haematol. 2001;  115 58-62 (III)
    CrossrefPubMedGoogle Scholar
  • 56 Endo T, Sakai T, Fujimoto K. et al . A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.  Bone Marrow Transplant. 2001;  27 433-436 (III)
    CrossrefPubMedGoogle Scholar
  • 57 Lau G K, He M L, Fong D Y. et al . Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation.  Hepatology. 2002;  36 702-709 (III)
    CrossrefPubMedGoogle Scholar
  • 58 Munster T, Weis N M, Krogsgaard K. Polyarteritis nodosa and hepatitis B infection treated with lamivudine.  Ugeskr Laeger. 2002;  164 342-343 (III)
    PubMedGoogle Scholar
  • 59 Gupta S, Piraka C, Jaffe M. Lamivudine in the treatment of polyarteritis nodosa associated with acute hepatitis B.  N Engl J Med. 2001;  344 1645-1646 (III)
    CrossrefPubMedGoogle Scholar
  • 60 ter B org F, Smorenburg S, de Man R A. et al . Recovery from life-threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy.  Dig Dis Sci. 1998;  43 2267-2270 (III)
    CrossrefPubMedGoogle Scholar
  • 61 Clark F L, Drummond M W, Chambers S. et al . Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma.  Ann Oncol. 1998;  9 385-387 (III)
    CrossrefPubMedGoogle Scholar
  • 62 Kazim S N, Wakil S M, Khan L A. et al . Vertical transmission of hepatitis B virus despite maternal lamivudine therapy.  Lancet. 2002;  359 1488-1489 (III)
    CrossrefPubMedGoogle Scholar
  • 63 Perrillo R, Schiff E, Yoshida E. et al . Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.  Hepatology. 2000;  32 129-134 (III)
    CrossrefPubMedGoogle Scholar
  • 64 Peters M, Hann H W, Martin P. et al . Hepatology. 2002;  36 374A (Ib)
    PubMed

Prof. Dr. med. H. E. Blum

Albert-Ludwigs-Universität, Innere Abteilung II

Hugstetter-Str. 55

79106 Freiburg

eMail: heblum@ukl.uni-freiburg.de